Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Nasal potential difference measurements in patients with atypical cystic fibrosis

M. Wilschanski, H. Famini, N. Strauss-Liviatan, J. Rivlin, H. Blau, H. Bibi, L. Bentur, Y. Yahav, H. Springer, M.R. Kramer, A. Klar, A. Ilani, B. Kerem, E. Kerem
European Respiratory Journal 2001 17: 1208-1215; DOI:
M. Wilschanski
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Famini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
N. Strauss-Liviatan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Rivlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Blau
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Bibi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Bentur
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Yahav
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. Springer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.R. Kramer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Klar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Ilani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Kerem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Kerem
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The diagnosis of cystic fibrosis (CF) is based on characteristic clinical and laboratory findings. However, a subgroup of patients present with an atypical phenotype that comprises partial CF phenotype, borderline sweat tests and one or even no common cystic fibrosis transmembrane conductance regulator (CFTR) mutations. The aim of this study was to evaluate the role of nasal potential difference (PD) measurements in the diagnosis of CF patients with an atypical presentation and in a population of patients suspected to have CF.

Nasal PD was measured in 162 patients from four different groups: patients with classical CF (n=31), atypical phenotype (n=11), controls (n=50), and patients with questionable CF (n=70). The parameter, or combination of nasal PD parameters was calculated in order to best discriminate all CF patients (including atypical CF) from the non-CF group.

The patients with atypical CF disease had intermediate values of PD measurements between the CF and non-CF groups. The best discriminate model that assigned all atypical CF patients as CF used: e(response to chloride-free and isoproterenol/response to amiloride) with a cut-off >0.70 to predict a CF diagnosis. When this model was applied to the group of 70 patients with questionable CF, 24 patients had abnormal PD similar to the atypical CF group. These patients had higher levels of sweat chloride concentration and increased rate of CFTR mutations.

Nasal potential difference is useful in diagnosis of patients with atypical cystic fibrosis. Taking into account both the sodium and chloride transport elements of the potential difference allows for better differentiation between atypical cystic fibrosis and noncystic fibrosis patients. This calculation may assist in the diagnostic work-up of patients whose diagnosis is questionable.

  • atypical phenotype
  • cystic fibrosis
  • genotype-phenotype
  • nasal potential difference

This study was supported, in part, by grants from the Chief Scientist of Israeli Health Ministry, The Israeli CF Foundation, and from the Joint Hebrew University – Shaare Zedek Research Fund, The Mirsky Foundation and Balint Charitable Trust

The diagnosis of cystic fibrosis (CF) is made by the presence of typical clinical findings and/or a family history of CF, together with abnormal sweat chloride values and/or the finding of two cystic fibrosis transmembrane conductance regulator (CFTR) mutations 1–3. However, an emerging number of patients present with an atypical phenotype of the disease. These patients may express only partial features of CF while essential characteristics of the disease may be absent. Such patients may suffer from respiratory disease with sufficient pancreatic function to maintain normal fat absorption, and/or male fertility, and may have normal or intermediate range sweat chloride levels 4–6. According to the consensus statement, by Rosenstein and Cutting 3, for diagnosis of CF these patients may be diagnosed as CF by the presence of two identified CFTR mutations. Another group of patients may present with phenotypes similar to CF but in only one organ system. These phenotypes may include nasal polyposis 7, 8, chronic sinusitis 9, recurrent pancreatitis 10, 11, male infertility due to congenital bilateral aplasia of the vas deferens (CBAVD) 12, allergic bronchopulmonary aspergillosis 13 or unexplained chronic lung disease with no other signs of CF 14–16. These patients have an increased incidence of CFTR mutations on one CFTR allele. The association between the clinical phenotype and CFTR dysfunction in these patients is unclear.

So far, >900 CFTR mutations have been identified (L.C. Tsui, CFTR mutations consortium, Hospital for Sick Children, Toronto, Ontario, Canada, personal communication), however, in most populations there are still many CF chromosomes with unidentified CFTR mutations. In addition, a significant number of patients carry mutations that are uncommon in their population. Patients with the questionable or atypical phenotype tend to carry rare CFTR mutations, mutations that have not yet been identified, or mutations in promotor regions or introns. The search for uncommon or unidentified mutations is complex, time-consuming and expensive. Therefore, it would be difficult to use mutation analysis to diagnose patients with atypical disease.

The basic defect of CF is due to a dysfunction of chloride ion flux across secretory epithelial cells. In normal epithelia, chloride ions enter the cell across the basolateral membrane and exit the apical surface down an electrochemical gradient via chloride channels. Regulation of these channels is by phosphorylation in response to an increase in intracellular cyclic adenosine monophosphate (cAMP) concentration. Sodium ions enter the apical surface of the cell from the lumen via amiloride-sensitive sodium channels, thus creating a voltage or potential difference (PD) across the apical surface of the cell. Knowles et al. 17 developed a technique to measure the PD across the nasal epithelium, as well as its response to various stimuli. They demonstrated that compared to a control population, in CF basal PD is increased, inhibition with amiloride is exaggerated and there is no significant change in PD after perfusion with chloride-free and isoproterenol solutions. According to the consensus statement, by Rosenstein and Cutting 3, for the diagnosis of CF, nasal PD may assist in the diagnosis or exclusion of CF. However, it has not been systematically evaluated in patients with atypical CF.

The aim of this study was to evaluate the role of nasal PD measurements in the diagnosis of CF cases with atypical presentation. The results of nasal PD measurements in patients with atypical CF were compared to those of patients with classical CF presentation and to normal controls. The results were then applied to a population of patients suspected of having CF.

Methods

Study subjects

The present study included 162 patients in four different groups. 1) A control group which comprised normal individuals or patients with non-CF lung disease, including five patients with primary ciliary dyskinesia, immune deficiency and chronic lung disease associated with autoimmune disorders (n=50, 19 males; age 30±5 yrs mean±sd). 2) A group of CF patients with typical disease (n=31, 19 males; age 18±8 yrs). CF was diagnosed by typical gastrointestinal and respiratory presentation together with elevated sweat chloride levels (performed in all the study patients according to the Gibson and Cooke methodology 18). 3) Patients with atypical CF (n=11, 9 males; age 26±12 yrs). These patients have partial or mild CF presentation characterized by sinopulmonary disease and pancreatic sufficiency together with CBAVD, or late diagnosis with milder phenotype. Table 1⇓ shows the clinical characteristics of these patients. In all patients, CF diagnosis was made by elevated sweat chloride levels and/or by the presence of two CFTR mutations when sweat chloride levels were normal or borderline. The mutations carried by these patients have previously been associated with atypical or variable disease presentation 4, 5, 19–21. 4) Patients with clinical presentation suspected to be CF (n=70, 42 males; age 17±12 yrs). These patients were referred for nasal PD measurements from various clinics in Israel. They had at least one of the following clinical features that raised the possibility of CF, but they lacked the criteria required for CF diagnosis. Fifty-nine patients had sinopulmonary disease including one or more of the following: chronic severe asthma resistant to conventional therapy, recurrent pulmonary infections, bronchiectasis, chronic severe pansinusitis, and nasal polyposis. Four patients had azoospermia or oligospermia. Respiratory disease was evaluated by the presence of clinical symptoms, chest radiograph interpretation, pulmonary function tests and sputum cultures. Primary ciliary dyskinesia was excluded by the absence of ciliary ultrastructural abnormalities. Eleven patients suffered from gastrointestinal manifestations including pancreatic insufficiency; three patients had recurrent pancreatitis, and one patient was asymptomatic and was identified during a family screening as homozygous for the 5T allele. The mean±sd sweat chloride levels in this group were 44±19 mmol·L−1 (range 15–83 mmol·L−1).

View this table:
  • View inline
  • View popup
Table 1—

Clinical data of patients with atypical cystic fibrosis disease

All patients were tested for the presence of all known CFTR mutations in Israel 22 including the 5T allele 19.

Nasal potential difference measurements

Transepithelial nasal PD was determined by measuring the PD between a fluid-filled exploring bridge on the nasal mucosa and a reference bridge (21-gauge needle filled with Ringers solution in 4% agar) inserted into the subcutaneous space of the forearm. Both bridges were linked by calomel electrodes to a high-impedance, low-resistance buffer amplifier. Using direct vision with an otoscope, the exploring catheter was advanced through the inferior meatus of both nostrils and PD was recorded at various sites. After consistent baseline PD measurements had been obtained, the effect of amiloride (1×10−4 M) superfusion was evaluated. The resultant change in PD was recorded and expressed as both an absolute change and as a percentage change from the baseline maximum PD value. In order to study nasal chloride permeability and cAMP activation of chloride permeability, a large chloride chemical gradient across the apical membrane was generated by superfusion of the nasal mucosa with a chloride-free solution containing 1×10−4 mol·L−1 amiloride at a rate of 5 mL·min−1. Following this, the mucosa was perfused with the same solution with the addition of isoproterenol (1×10−5 mol·L−1). The change in voltage response over the final 6 min served as an index of epithelial chloride transport.

Deoxyribonucleic acid sequence determination and mutation analysis

Deoxyribonucleic acid (DNA) sequences spanning individual exons of the CF gene were amplified by polymerase chain reaction (PCR) with oligonucleotide primers located in the respective flanking introns of the CF gene 23, 24. The amplified genomic DNA fragments eluted from 5% polyacrylamide gels were extracted with chloroform and subjected to the dideoxy-chain termination sequencing method as described, using the US Biochemicals Sequenase kit (Cleveland, OH, USA) with either one of the PCR primers or internal oligonucleotides as sequencing primers. Following the identification of a specific mutation in an individual, the entire CF population studied was detected for this mutation using previously described methods 22. Analysis of the polythymidine tract at the branch/acceptor site of exon 9 was performed as previously described 19.

Statistical analysis

Mean values and standard deviations (sds) were computed for all nasal PD parameters: basal PD, response to amiloride perfusion in mV and per cent change, and response to chloride-free and isoproterenol solutions, for each of the CF, atypical CF, and non-CF control groups. Comparison between the three patient groups was performed separately on each parameter, using multiple comparison methods with a significance level of 0.05. For multiple comparisons, analysis of variance (ANOVA) was used with the Bonferroni and Dunnetts procedures for the post hoc tests, as appropriate.

The results of nasal PD measurements included several parameters. Discriminant analysis was used in order to explore which parameter, or combination of parameters, can best discriminate all CF patients (including atypical CF) from the non-CF group. The parameters used were basal PD, response to amiloride perfusion in mV and per cent change, and response to chloride-free and isoproterenol solutions. Various combinations and functional forms of the relevant variables were tested to achieve the best separation between the groups by the discriminant function. Fisher's linear discriminant function was applied to suggest a cut-off point between CF and non-CF patients.

The estimated model was then used to assign the 70 suspected CF patients into two groups: CF or non-CF. The suspected CF group, assigned by the model as CF, was then compared to each of the two groups of CF patients, CF and atypical CF using Dunnetts 25 test for each of the PD parameters. Comparison of values of sweat chloride and forced expiratory volume in one second (FEV1) between the suspected CF patients who were assigned CF and those who were assigned as non-CF, was performed using an unpaired t-test, separately on each of these two parameters. The Chi-squared test was performed to test the association between genotypes and the predicted groups. Data are presented as mean±sd unless otherwise stated.

The Human Ethics Committee of The Israeli Ministry of Health approved the study and informed written consent was obtained from all the patients or parents.

Results

All patients with classical CF had typically abnormal nasal PD measurements compared to controls (table 2⇓). CF patients had increased sodium transport, as demonstrated by elevated negative basal PD (p<0.001) (fig. 1a⇓), exaggerated response to amiloride perfusion in absolute values (p<0.001) (fig. 1b⇓) and per cent change from basal PD (p=0.016), and no chloride transport, as demonstrated by lack of response to perfusion with isoproterenol and chloride-free solution (p<0.001) (fig. 1c⇓).

Fig. 1.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.—

a) Basal potential difference (PD) in cystic fibrosis (CF) (n=31), atypical CF (n=11) and control patients (n=50). Note that some atypical CF patients had normal basal PD. b) The change in PD following amiloride perfusion in CF (n=31), atypical CF (n=11) and control patients (n=50). c) The change in PD following perfusion of chloride (Cl)-free and isoproterenol solution in CF (n=31), atypical CF (n=11) and control patients (n=50). d) The exponent of the ratio: response to chloride-free+isoproterenol/response to amiloride in CF (n=31), atypical CF (n=11) and control patients (n=50).

View this table:
  • View inline
  • View popup
Table 2—

Nasal potential difference (PD) results of cystic fibrosis (CF) patients, control, patients with atypical CF disease, and patients with questionable CF disease

The patients with atypical CF disease, as a group, had intermediate PD measurements between the CF and non-CF groups (table 2⇑). As shown in figures 1a, 1b and 1c⇑, compared to the control group, patients with atypical CF had significantly higher negative basal PD (p<0.001), increased response to amiloride perfusion in absolute values (p<0.001), higher per cent change from baseline (p=0.02), and no response to isoproterenol and chloride-free solution (p<0.001). Similar to the classical CF group, patients with atypical CF had absent chloride transport (no response to perfusion with isoproterenol and chloride-free solution) (p=0.42), and increased response to amiloride perfusion in per cent change from baseline (p=1.0). However, the patients with atypical CF had lower basal PD (p<0.001) and decreased amiloride response in absolute values (p=0.001), when compared to classical CF.

Therefore, the discriminate analysis was used to explore which parameter, or combination of parameters best classify the atypical CF patients as CF and discriminate them from the non-CF group. The best discriminate model is one using the exponent of the ratio:response to isoproterenol and chloride-free/response to amiloride (e(response to chloride-free and isoproterenol/response to amiloride)) as the best discriminative variable between the groups. Using Fisher's linear discriminate function, the cut-off is given by the inequality (e(response to chloride-free and isoproterenol/response to amiloride)) >0.70, which is equivalent to the actual ratio, without the exponent, of the sum of the response to isoproterenol and chloride-free/response to amiloride >−0.35 to be a CF patient (fig. 1d⇑).

The group of 70 patients with questionable CF was then studied. The basal PD in this group was −23±10 mV, the change in PD following amiloride perfusion was 13±8.5 mV, and the repolarization following superperfusion with chloride-free solution and isoproterenol was −6.3±5.3 mV. However, when the statistical model was applied to this group of patients, two distinct patterns of the PD results emerged, enabling the segregation of these patients into two groups: 1) 46 patients with normal measurements similar to the non-CF controls, questionable CF with normal PD (QCF-non-CF); and 2) 24 patients with abnormal measurements, questionable CF with abnormal PD (QCF-CF). As shown in table 2⇑, there were significant differences in all the PD parameters between the two groups including basal PD, response to amiloride superperfusion, response to chloride-free solution and isoproterenol superperfusion. However, none of these parameters discriminated clearly between the two groups (figs. 2a and b⇓).

Fig. 2.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.—

a) The change in potential difference (PD) following amiloride solution plotted against basal PD in questionable CF (•; n=24) and questionable non-CF patients (○; n=46). b) The change in PD following chloride-free and isoproterenol solution plotted against the exponent of the ratio:response to isoproterenol and chloride-free/response to amiloride in questionable CF (•; n=24) and questionable non-CF patients (○; n=46).

The group of QCF-CF patients was compared to each of the two groups of CF patients: classical CF and atypical CF. The QCF-CF group had measurements similar to the atypical CF group in basal PD (p=0.46), in response to amiloride perfusion (p=0.18) and in response to chloride-free solution and isoproterenol superperfusion (p=0.77), but still significantly different in all these parameters from the classical CF patients (p<0.001, <0.001 and =0.002, respectively). This showed that the QCF-CF group was similar to the atypical CF group.

Clinical parameters and genotype analysis of the two groups of patients are shown in table 3⇓. There was no difference in pulmonary function between both groups. However, the group of patients with QCF-CF had a lower mean age and significantly higher mean sweat chloride levels compared to that of the QCF-non-CF group.

View this table:
  • View inline
  • View popup
Table 3—

Clinical parameters of patients referred with questionable Cystic Fibrosis (GF)

Genotype analysis for the known mutations in the Israeli population 21 revealed that none of the patients from the QCF-non-CF group carried two CFTR mutations or the 5T allele on both chromosomes, apart from one patient homozygous for 5T, compared to five patients (22%) in the QCF-CF group, p<0.001 (table 3⇑). The frequency of the 5T allele in the QCF-CF group was 17.4%, significantly higher than the 6% frequency in the general population 19 (p=0.04), but not significantly higher than the 10.5% frequency in the QCF-non-CF. Interestingly, the frequency of ΔF508 among the QCF-non-CF was 8.5% which was significantly higher than the frequency of 1.4% in the Israeli population 26 (p<0.01).

Discussion

Nasal PD measurement is a well-established electrophysiological tool for the diagnosis of CF and for the monitoring of treatment protocols both in animal models 27, 28 and CF patients 29–35. The present study shows that this test is abnormal in patients with atypical CF disease. However, some patients with atypical CF may have borderline or even normal basal PD and amiloride response, but characteristically abnormal chloride conductance. It is therefore imperative not to rely on the basal PD only and to complete the PD measurement with chloride-free and isoproterenol perfusion before a diagnosis of CF is ruled out. The chloride secretory response has high sensitivity and specificity for normal versus CF or atypical CF. In a similar manner to the atypical CF patients in the present study, the patients in a study by Walker et al. 36 carried mutations associated with milder pulmonary disease and had typical abnormal PD measurements. Likewise, Pradal et al. 37 measured nasal PD in males with CBAVD and showed that a subgroup of patients had normal basal PD, but abnormal chloride transport values. In another study, this group measured the basal PD in a group of CF patients with borderline sweat chloride levels and found that some of them had normal basal PD measurements 38. Danner et al. 39 compared nasal PD between controls, proven CF patients and a group of patients with disseminated bronchiectasis and found that the latter group had normal PD.

Although patients with atypical CF may have abnormal chloride transport, the cut-off where a diagnosis of CF can be made is not always clear. According to the model in the present study, the technique of nasal PD might best define atypical CF patients as CF by applying a statistical model using the ratio of the response to isoproterenol and chloride-free/response to amiloride. This model classified all atypical CF patients as CF and was found to be the best to clearly discriminate them from the non-CF subjects. It is interesting to note that this function considers both chloride transport (expressed by response to isoproterenol and chloride-free solutions) and sodium transport (expressed by response to amiloride). An actual value of >−0.35 (equivalent to the exponential ratio of >0.7) was found to predict a CF diagnosis. However, further studies in other laboratories and on a larger number of patients are required to confirm the present findings.

Patients presenting with disease resembling the atypical CF phenotype may share signs and symptoms with other diseases, such as severe asthma, immune deficiency, ciliary dyskinesia, postinfectious or idiopathic segmental bronchiectasis or idiopathic pancreatitis. Furthermore, in these patients, genetic analysis usually reveals that they do not carry two common CFTR mutations. Pursuing a thorough CFTR mutation search in cases where CF diagnosis is uncertain is prohibitive. It is therefore, difficult to know if all these patients have CF. The results of the present study in a large group of patients in whom diagnosis of CF cannot be established or ruled-out by sweat test or mutation analysis, show that a subgroup of patients had nasal PD studies with abnormal response to chloride-free and isoproterenol solutions and intermediate values of basal PD and amiloride depolarization. These PD measurements were similar to the group of proven atypical CF patients. These patients with abnormal PD also had higher sweat chloride values and a significantly higher incidence of patients carrying two CFTR mutations.

Thus, it is likely that these patients have atypical CF disease. However, further studies including search for the rare CFTR mutations, whole genome scan, or CFTR functional studies will be required to associate their disease with CFTR dysfunction.

Wilson et al. 40 studied 11 patients with questionable diagnosis of CF who underwent nasal PD as part of their diagnostic evaluation. Two of their patients had an abnormal PD and subsequently both were found to carry the 5T allele on one chromosome. In the present study, of the 24 patients with QCF who had an abnormal PD, five patients were found to carry two CFTR mutations, four of them the 5T allele on one chromosome. The 5T allele has been described as a variant with partial penetrance causing disease with an extremely variable clinical presentation 19. Recently, it has been shown that two patients with respiratory symptoms and carrying the 5T allele had abnormal chloride transport 41. Thus, the PD measurements in the present study patients confirm previous clinical and molecular observations that the 5T allele might be associated with atypical CF disease 19, 23.

An interesting finding was the increased frequency of the ΔF508 mutation among patients with questionable CF and normal nasal PD. It is possible that the disease in some of the patients with normal PD might be associated with CFTR dysfunction, which together with environmental or other genetic factors (modifier genes) lead to the development of pulmonary disease. Numerous studies have reported increased frequency of the ΔF508 mutation among patients with chronic bronchopulmonary disease including chronic bronchitis, bronchiectasis, allergic bronchopulmonary aspergillosis 12–16, 42 and among patients with asthma 43, 44. All these observations suggest that heterozygosity to the ΔF508 mutation may predispose to recurrent or chronic pulmonary diseases.

In conclusion, nasal potential difference measurements are useful in the diagnosis of patients with atypical cystic fibrosis disease. It is imperative not to rely on the basal potential difference and to complete the potential difference measurements with chloride-free and isoproterenol superperfusion before a diagnosis of cystic fibrosis is ruled-out. The cut-off point between normal and abnormal chloride transport should be determined in each laboratory. Patients with questionable cystic fibrosis and with potential difference measurements showing abnormal chloride and sodium transport are likely to have atypical cystic fibrosis. Thus, further studies to determine the frequency of cystic fibrosis transmembrane conductance regulator mutations in this patient population are needed.

  • Received October 25, 2000.
  • Accepted March 6, 2001.
  • © ERS Journals Ltd

References

  1. ↵
    Rosenstein BJ, Zeitlin PL. Cystic fibrosis. Lancet 1988;351:277–281.
  2. Stern RC. Current concepts: the diagnosis of cystic fibrosis. N Engl J Med 1997;336:487–491.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. J Pediatr 1998;132:589–595.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Stewart B, Zabner J, Shuber AP, Welsh MJ, McCray B Jr. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis. Am J Respir Crit Care Med 1995;151:899–903.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Highsmith WE, Lauraneli H, Burch MS, et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. N Engl J Med 1994;331:974–980.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Augarten A, Kerem B, Yahav Y, et al. Mild cystic fibrosis and normal or borderline sweat test in patients with the 3849+10 kb C->T mutation. Lancet 1993;342:25–26.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Irving RM, McMahon R, Clark R, Jones NS. CFTR mutations in severe nasal polypsis. Clin Otolaryngol 1997;22:519–521.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Burger J, Macek M Jr, Stuhrmann M, Reis A, Krawczak M, Schmidtke J. Genetic influences in the formation of nasal polyps. Lancet 1997;337:974.
    OpenUrlCrossRef
  9. ↵
    Wiatrak BJ, Meyer CM, Cotton RT. Cystic fibrosis presenting with sinus disease in children. Am J Dis Child 1993;147:258–260.
    OpenUrlCrossRefPubMed
  10. ↵
    Cohn JA, Friedman KJ, Noone PG, Knowles MR, Silverman LM, Jowell PS. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis. N Engl J Med 1998;339:653–658.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998;339:645–652.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    Chillon M, Casals T, Mercier B, et al. Mutations in the cystic fibrosis gene in patients with congenital bilateral absence of the vas deferens. N Engl J Med 1995;332:1475–1480.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    Miller PW, Hamosh A, Macek M Jr, et al. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations in allergic bronchopulmonary aspergillosis. Am J Hum Genet 1995;59:45–51.
    OpenUrl
  14. ↵
    Giorodon E, Cazeneuve C, Lebargy F, et al. CFTR mutations in adults with disseminated bronchiectasis. Eur J Hum Genet 1997;5:149–155.
    OpenUrlPubMedWeb of Science
  15. Dumur V, Lafitte JJ, Gervais R, et al. Abnormal distribution of cystic fibrosis ΔF508 allele in adults with chronic bronchial hypersecretion. Lancet 1990;335:1340.
    OpenUrl
  16. ↵
    Gervais R, Lafitte JJ, Dumur V, et al. Sweat chloride and ΔF508 mutation in chronic bronchitis or bronchiectasis. Lancet 1993;342:997.
    OpenUrlPubMedWeb of Science
  17. ↵
    Knowles MR, Paradiso AM, Boucher RC. In vivo nasal potential difference: techniques and protocols for assessing efficacy of gene transfer in cystic fibrosis. Hum Gene Ther 1993;6:445–455.
    OpenUrl
  18. ↵
    Gibson LE, Cooke RE. A test for concentration of electroytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 1959;23:545–549.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Kerem E, Rave-Harel N, Augarten A, et al. A cystic fibrosis transmembrane conductance regulator splice variant with partial penetrance associated with variable cystic fibrosis presentations. Am J Respir Crit Care Med 1997;155:1914–1920.
    OpenUrlCrossRefPubMedWeb of Science
  20. Feldmann D, Rochemaure J, Plouvier E, Magnier C, Chauve C, Aymard P. Mild course of cystic fibrosis in an adult with the D1152H mutation. Clin Chem 1995;41:1675.
    OpenUrlFREE Full Text
  21. ↵
    Kerem E, Nissim-Rafinia M, Argaman Z, et al. A missense cystic fibrosis transmembrane conductance regulator mutation with variable phenotype. Pediatrics 1997;100:E5.
  22. ↵
    Kerem E, Kalman YM, Yahav Y, et al. Highly variable incidence of cystic fibrosis and different mutation distribution among different Jewish ethnic groups in Israel. Hum Gene 1995;96:193–197.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Rave-Harel N, Kerem E, Nissim-Rafinia M, et al. The molecular basis of partial penetrance of splice mutations in cystic fibrosis. Am J Hum Genet 1997;60:87–94.
    OpenUrlPubMedWeb of Science
  24. ↵
    Shoshani T, Kerem E, Szeinberg A, et al. Similar levels of mRNA from the W1282X and the ΔF508 cystic fibrosis alleles in nasal epithelial cells. J Clin Invest 1994;93:1502–1507.
  25. ↵
    Dawson-Saunders B, Trapp RG, In: Basic and Clinical Biostatistics. Norwalk, Appleton and Lange, 1990; pp. 8–12.
  26. ↵
    Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet 1992;51:951–956.
    OpenUrlPubMedWeb of Science
  27. ↵
    Wilschanski M, Rozmahel R, Beharry S, et al. In vivo measurements of ion transport in long-living mice. Biochem Biophys Res Commun 1996;219:753–759.
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    Ramjeesingh M, Huan LJ, Li C, et al. Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF mice. Hum Gene Ther 1998;9:521–528.
    OpenUrlPubMedWeb of Science
  29. ↵
    Knowles MR, Hohneker KW, Zhou Z, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1998;333:823–831.
  30. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium-4-phenylbutyrate in ΔF508 homozygous cystic fibrosis patients. Am J Respir Crit Care Med 1998;157:484–490.
  31. Zabner J, Ramsey BW, Meeker DP, et al. Repeat adminstration of an adenovirus vector encoding cystic fibrosis transmembrane regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504–1511.
    OpenUrlCrossRefPubMedWeb of Science
  32. Zabner J, Chen SH, Meeker D, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1998;100:1529–1537.
    OpenUrl
  33. Arispe N, Ma J, Jacobson KA, Pollard HB. Direct activation of cystic fibrosis transmembrane conductance regulator (CFTR) by the alkylxanthine 8-cyclopentyl-1 3-dipropylxanthine (CPX) and 1,3-diallylcyclohexa manthine (DAX). J Biol Chem 1998;273:5727–5734.
    OpenUrlAbstract/FREE Full Text
  34. Kelley TJ, Thomas K, Milram LJ, Drumm MK. In vivo activation of the cystic fibrosis transmembrane conductance regulator mutant ΔF508 in murine nasal epithelium. Proc Natl Acad Sci USA 1998;94:2604–2608.
  35. ↵
    Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo controlled trial. Lancet 1999;353:947–954.
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    Walker LC, Venglarik CJ, Gervais A, et al. Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am J Respir Crit Care Med 1997;155:1684–1689.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    Pradal U, Castellani C, Delmarco A, Mastella G. Nasal potential difference in congenital bilateral absence of the vas deferens. Am J Respir Crit Care Med 1998;158:896–901.
    OpenUrlPubMedWeb of Science
  38. ↵
    Delmarco A, Pradal U, Cabrini G, Bonizzato A, Mastella G. Nasal potential difference in cystic fibrosis patients presenting borderline sweat test. Eur Respir J 1997;10:1145–1149.
    OpenUrlAbstract
  39. ↵
    Danner I, Boisseau P, Chailleux E, Escande D. Respiratory epithelial ion transport in patients with disseminated bronchiectasis. Eur Respir J 1999;13:1276–1280.
    OpenUrlAbstract/FREE Full Text
  40. ↵
    Wilson D, Ellis L, Zielenski J, et al. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. Pediatr 1998;132:596–599.
  41. ↵
    Noone PG, Pue CA, Zhou Z, et al. Lung disease associated with the IVS8 5T allele of the CFTR gene. Am J Respir Crit Care Med 2000;162:1919–1924.
    OpenUrlPubMedWeb of Science
  42. Puechal X, Fajac I, Bienvenu T, et al. Increased frequency of cystic fibrosis ΔF508 mutation in bronchiectasis associated with rheumatoid arthritis. Eur Respir J 1999;13:1281–1287.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    Lazaro C, de Cid R, Sunyer J, et al. Missense mutations in the cystic fibrosis gene in adult patients with asthma. Hum Mutat 1999;14:510–519.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    Dahl M, Tybjaerg-Hansen A, Lange P, Nordestgaard BG. Delta F508 heterozygosity in cystic fibrosis and susceptibility to asthma. Lancet 1998;351:1911–1913.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
View this article with LENS
Vol 17 Issue 6 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Nasal potential difference measurements in patients with atypical cystic fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Nasal potential difference measurements in patients with atypical cystic fibrosis
M. Wilschanski, H. Famini, N. Strauss-Liviatan, J. Rivlin, H. Blau, H. Bibi, L. Bentur, Y. Yahav, H. Springer, M.R. Kramer, A. Klar, A. Ilani, B. Kerem, E. Kerem
European Respiratory Journal Jun 2001, 17 (6) 1208-1215;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Nasal potential difference measurements in patients with atypical cystic fibrosis
M. Wilschanski, H. Famini, N. Strauss-Liviatan, J. Rivlin, H. Blau, H. Bibi, L. Bentur, Y. Yahav, H. Springer, M.R. Kramer, A. Klar, A. Ilani, B. Kerem, E. Kerem
European Respiratory Journal Jun 2001, 17 (6) 1208-1215;
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Cystic fibrosis neutrophils have normal intrinsic reactive oxygen species generation
  • Absorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway
  • Long-term effects of a partially supervised conditioning programme in cystic fibrosis
Show more Original Articles: Cystic fibrosis

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society